Background: For recurrent biliary tract cancer, chemotherapy is the standard treatment. However, the efficacy of surgery is unknown. Here, the prognostic benefit of surgery for recurrent biliary tract cancer was investigated. Methods: Data of 206 patients who underwent surgery for biliary tract cancer between 2005 and 2015 were retrospectively analyzed. Of these, 107 recurrent patients were divided into two groups, surgery (n = 14) and non-surgery (n = 93) groups. In the latter group, 45 patients received chemotherapy and 48 received best supportive care. Results: Of the total 121 sites of recurrence, the liver was the most common (n = 41), followed by locoregional recurrence (n = 32) and lymph nodes (n = 18). Surgery was performed in the 14 patients with recurrence, comprising nine patients with intrahepatic cholangiocarcinoma, three with perihilar cholangiocarcinoma, one with distal cholangiocarcinoma and one with gallbladder carcinoma. Survival after recurrence was significantly better after surgery than after chemotherapy or best supportive care (38% vs. 5.3% vs. 0% at 3 years and 19% vs. 5.3% vs. 0% at 5 years; P < 0.0001). Multivariate analysis identified the residual status of the primary tumor (hazard ratio = 1.58, 95% confidence interval = 1.00-2.44; P = 0.047), time to recurrence ≥1 year (hazard ratio = 0.62, 95% confidence interval = 0.39-0.97; P = 0.037) and surgery for recurrence (hazard ratio = 0.32, 95% confidence interval = 0.14-0.62; P < 0.001) as independent prognostic factors. Conclusions: Surgery for recurrent biliary tract cancer may prolong survival in patients with time to recurrence ≥1 year.
Introduction
For biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder carcinoma, complete resection is the only potentially curative treatment option (1, 2) . Recent advances in surgical techniques and perioperative management have offered increased resectability and improved surgical outcomes (3, 4) . However, even after curative resection, more than half of patients develop recurrence and long-term outcomes remain unsatisfactory (5, 6) .
Chemotherapy is considered the standard treatment for recurrent BTC (7) . However, little is known about the efficacy of surgical resection for recurrent BTC, as published studies on surgery for recurrent BTC are limited (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .
The aim of this study was to evaluate the survival benefit of surgery for recurrent BTC following radical surgery. Moreover, a systematic review of the literature was performed to confirm this survival benefit.
Patients and methods

Patients
A prospectively collected database of 206 patients who underwent resection for BTC from January 2005 to December 2015 in our department was retrospectively analyzed. Of these patients, five (2.4%) died of postoperative complications. The primary cancer in the remaining 201 patients was intrahepatic cholangiocarcinoma in 60 patients, perihilar cholangiocarcinoma in 45, distal cholangiocarcinoma in 66 and gallbladder carcinoma in 30. Of these 201 patients, 107 (53%) developed recurrent disease during the study period. Among these, 14 patients underwent surgical resection for recurrence with curative intent (surgery group), whereas 93 did not (non-surgery group). A total of 107 patients with recurrent disease after primary tumor resection (surgery group, n = 14; non-surgery group, n = 93) participated as subjects in this retrospective study.
Standard patient demographic and clinicopathological data were collected, which included patient age and sex and tumor-specific characteristics. Data on tumor stage were also collected according to 7th edition of The Union for International Cancer Control TNM Classification of Malignant Tumours. Resection margin status was recorded and classified as microscopically negative (R0), microscopically positive (R1) or macroscopically positive (R2). Data regarding treatment details of the primary tumor also were collected, including the type of surgery and the use of adjuvant chemotherapy. Complications were classified according to the Clavien-Dindo classification system. Complications greater than Grade III were considered severe.
With regard to the initial surgery for primary disease, most patients with intrahepatic cholangiocarcinoma underwent hemihepatectomy or more extended resection with regional lymph node dissection. For small peripheral intrahepatic cholangiocarcinoma, partial hepatectomy without lymph node dissection was performed. For patients with perihilar cholangiocarcinoma, hepatectomy with en bloc resection of the caudate lobe and extrahepatic bile duct, and regional lymph node dissection was applied in principle. For patients with distal cholangiocarcinoma, pancreaticoduodenectomy with regional lymph node dissection was performed, with the exception of a few patients with poor liver function or early cancer. For patients with gallbladder carcinoma, various types of surgery were performed, from simple cholecystectomy to extended liver resection combined with pancreaticoduodenectomy, according to the extent of the cancer.
After resection, all patients were followed regularly on an outpatient basis every 3-6 months by clinical examinations and computed tomography for the first 2 years, and every 6 months afterward.
With regard to chemotherapy, systemic chemotherapy with mitomycin C, 5-fluorouracil, oxaliplatin or capecitabine was administered to patients with advanced BTC. Gemcitabine hydrochloride and tegafur-gimeracil-oteracil-potassium (S-1) were authorized for treating BTC in Japan in 2006 and 2007, respectively. Therefore, 20 patients (19%) with advanced cancer received adjuvant chemotherapy after primary surgery. Of these, 16 patients received adjuvant chemotherapy with gemcitabine and four received S-1. For disease relapse, chemotherapy was arbitrarily used according to the preference of the surgeon or oncologist and/or the general condition of the patient. For recurrence, 45 patients underwent chemotherapy with gemcitabine (n = 20), gemcitabine plus cisplatin (n = 11), S-1 (n = 9), or other regimens (n = 5).
Recurrence was confirmed by computed tomography and/or magnetic resonance imaging. Positron emission tomography was also used when needed. The site was categorized as locoregional or distant (liver, peritoneum, distant lymph node, chest or abdominal wall, or extra-abdominal organ).
Surgical resection was considered when the recurrence was solitary and technically resectable in the presence of good performance status, regardless of the primary site or pattern of recurrence. Aggressive surgery was indicated for recurrence after 1 year or more. Of the 14 patients who underwent surgery for recurrence, one underwent surgery at 1.5 years after chemotherapy without tumor progression.
Systematic review of literature
To understand the outcomes of surgery for recurrent BTC, a systematic review of published work on this topic was performed based on the data available in the PubMed database (1978-March 2016) using the following terms: 'cholangiocarcinoma,' 'gallbladder carcinoma,' 'recurrence' and 'surgery.' Related citations in the retrieved articles were also included, while case reports were excluded. The median survival times and survival rates at 3 and 5 years after recurrence were analyzed.
Statistical analysis
Statistical analysis was performed using JMP 11 software (SAS Institute Inc., Cary, NC, USA). Categorical variables were analyzed using the chi-square or Fisher's exact test, as appropriate. Continuous variables were analyzed using the Wilcoxon rank-sum test. Survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test. Prognostic factors for survival were identified using multivariate Cox proportional hazards models. All statistical analyses were two-tailed and P-values < 0.05 were considered statistically significant.
Results
Patient demographics
Of a total of 107 patients with recurrent disease after primary tumor resection, 14 underwent surgery, 45 received chemotherapy and 48 received BSC. Among the 107 patients, 73 (87%) were men and 34 (13%) were women, with a median age of 69.5 (range, 46-85) years. There were 121 sites of recurrence in these 107 patients. The liver was the most common site of recurrence, followed by locoregional recurrence, the lymph nodes, the lungs and the peritoneum (Fig. 1) . Overall, 28 patients (26%) had locoregional recurrence alone and the remaining 79 had distant metastasis with or without locoregional recurrence. The primary cancer in the 107 study patients was intrahepatic cholangiocarcinoma in 36, perihilar cholangiocarcinoma in 30, distal cholangiocarcinoma in 30 and gallbladder carcinoma in 11. The incidence of recurrence was 60% (36/60) for intrahepatic cholangiocarcinoma, 67% (30/45) for perihilar cholangiocarcinoma, 44% (30/66) for distal cholangiocarcinoma and 37% (11/30) for gallbladder carcinoma. The median time from the initial surgery to surgery for recurrence was 2.3 years for intrahepatic cholangiocarcinoma, 1.0 year for perihilar cholangiocarcinoma, 1.3 years for distal cholangiocarcinoma and 1.9 years for gallbladder carcinoma.
Clinicopathological factors were compared between the 14 patients who underwent surgery for recurrence and the 93 non-surgery patients (Table 1 ). There were no statistically significant differences in the age and sex of the patients or the location and histology of primary disease. Tumor progression was similar except for lymph node metastasis, which was more frequent in the non-surgery group (21% vs. 58%, P = 0.019). The median time to recurrence was significantly longer in the surgery group (1.6 vs. 0.8 years, P = 0.005).
Surgery for recurrence
A total of 23 procedures for recurrence were performed in 14 patients, including once in 11 patients, twice in one, three times in one, and seven times in one. Several types of surgery were performed according to the site of recurrence. Of the two patients with locoregional recurrence, one underwent right hepatectomy with extrahepatic bile duct resection and with regional lymph node dissection and the other underwent pancreaticoduodenectomy. Chest or abdominal resection was performed for chest or abdominal wall recurrence (n = 2), both of which were recurrence of the percutaneous transhepatic biliary drainage tract. Partial hepatectomy was performed for solitary liver metastasis (n = 4). Partial lung resection was performed for solitary lung metastasis (n = 1). Of the four patients who underwent dissection for distant lymph node metastasis, two had hilar lymph node metastasis and one had periaortic lymph node metastasis. One patient with peritoneal recurrence had a solitary seeding in the abdominal cavity and underwent partial colectomy because of colonic obstruction. The morbidity and mortality rates were 0% and 0%, respectively. The clinical courses and the timings and types of surgery of 14 patients are summarized in Fig. 2 . Nine of these patients died of disease, while nine survived for >3 years, seven survived for >5 years and four survived for >8 years after the initial surgery.
Survival analysis
Survival after surgery for primary cancer was significantly better in the 14 patients who underwent surgery for recurrence than for the 45 patients who received chemotherapy and the 48 patients who received BSC (62% vs. 17% vs. 13% at 3 years and 54% vs. 7.4% vs. 5% at 5 years; P = 0.0006) (Fig. 3A) . Survival after recurrence was also significantly better in the surgery group than in the chemotherapy group and the BSC group (38% vs. 5.3% vs. 0% at 3 years and 19% vs. 5.3% vs. 0% at 5 years; P < 0.0001) (Fig. 3B) . Of the 14 patients, three survived for >5 years after surgery for recurrence, including one who died of disease 5.1 years after surgery, and the remaining two are now alive with recurrence. The sites of recurrence in the three patients varied, but the time to recurrence was >2 years in all patients. One patient in the BSC group developed recurrent disease 8 years after surgery.
Twelve clinicopathological variables were analyzed as potential prognostic factors after recurrence in the 107 patients (Table 2) . Univariate analysis identified age (P = 0.027), residual status of the primary tumor (P = 0.044), time to recurrence (P = 0.0027) and surgery for recurrence (P < 0.001) as significant prognostic factors. Multivariate analysis identified the residual status of the primary tumor [hazard ratio (HR) = 1.58; 95% confidence interval (CI) = 1.00-2.44; P = 0.047], time to recurrence ≥1 year (HR = 0.62; 95% CI = 0.39-0.97; P = 0.037) and surgery for recurrence (HR = 0.32; 95% CI = 0.14-0.62; P < 0.001) as independent prognostic factors.
Systematic review
Ten studies were identified through the systematic review (Table 3 ) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . A total of 220 patients underwent surgery for recurrent BTC, including our cases. The median survival time after recurrence was 26.1 (range, 10-66.6) months and the survival rates at 3 and 5 years after recurrence were 51.4% (range, 29%-100%) and 29% (range, 0%-51.4%), respectively.
Discussion
This study revealed that surgery for recurrent BTC is feasible and conveys significant survival benefits. According to the systematic review of the literature, surgical resection can be considered as a therapeutic option in select patients.
Chemotherapy is the standard strategy for most patients with recurrent BTC and good performance status. After a large-scale randomized control trial for unresectable or relapsed BTC (18), gemcitabine plus cisplatin therapy has become the standard first-line treatment for such patients. However, chemotherapy is palliative in principle, and long-term survival cannot be expected with a median survival time of~12 months (18−21) . In contrast, in this study, the overall 3-and 5-year survival rates of patients who underwent surgery for recurrence were 62% and 54%, respectively, and the 3-and 5-year survival rates after recurrence were 38% and 19%, respectively. Three patients survived for >5 years after surgery for recurrence. These results indicate that surgical resection should be considered as a treatment option for recurrent BTC.
A systematic review of the literature revealed a significant survival benefit of surgical resection for recurrent BTC (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , resulting in a median survival time of 26.1 (range, 10-66.6) months. Survival rates at 3 and 5 years after recurrence were 51.4% (range, 29%-100%) and 29% (range, 0%-51.4%), respectively. These findings together with those of this study suggest that surgery for recurrent BTC is feasible and provides a significant survival benefit.
Two recent studies of surgery for recurrent pancreatic adenocarcinoma conducted in high-volume centers (22, 23) both reported that patients with a longer initial recurrence-free interval are more likely to benefit from resection for recurrence. Regarding surgery for recurrent BTC, Takahashi et al. showed that patients with recurrence after >1 year from the initial surgery achieved good survival (9) . Therefore, 1 year was set as the cutoff value of time to recurrence in this study. The results of this study also demonstrated that a longer initial recurrent-free interval was associated with better prognosis. Surgical resection should be considered for recurrence after >1 year from the initial surgery.
Surgical resection is considered aggressively in our institution for solitary recurrence that is technically resectable in the presence of good performance status, regardless of the primary site or pattern of recurrence. These criteria are similar to those in previous reports (9, 10) . In addition, Noji et al. reported that an observation period of 3 months is necessary to exclude patients with rapidly growing or widely disseminating tumors (10) . However, because there is no definitive criterion concerning the observation period, further studies are necessary.
A limitation to this study was the relatively small number of patients and its retrospective nature. Therefore, we attempted to overcome this limitation by adding a systematic review of published work. However, there may have been a patient selection bias. Patients who were expected to achieve long-term survival may have been selected for surgery. In the surgery group, three of 14 patients survived for >5 years after surgery for recurrence. However, chemotherapy is palliative in principle and long-term survival cannot be expected.
In conclusion, surgery for recurrent BTC is feasible with a survival benefit in selected patients, especially for those with a long interval between the initial surgery and recurrence. I-CC indicates intrahepatic cholangiocarcinoma; P-CC, perihilar cholangiocarcinoma; D-CC, distal cholangiocarcinoma; GBC, gallbladder carcinoma.
